Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases.

Autor:	Kearsley-Fleet L; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Chang ML; Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA., Lawson-Tovey S; Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.; National Institute of Health Research Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, Manchester University NHS Foundation Trust, Manchester, UK., Costello R; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Fingerhutová Š; Department of Pediatrics and Adolescent Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Švestková N; Department of Pediatrics and Adolescent Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Belot A; Pediatric Nephrology, Rheumatology & Dermatology Department, HFME, Université Lyon-1, Hospices Civils de Lyon, Lyon, France., Aeschlimann FA; Pediatric Hematology-Immunology and Rheumatology Department, AP-HP, Hôpital universitaire Necker-Enfants malades, Paris, France., Melki I; Pediatric Hematology-Immunology and Rheumatology Department, AP-HP, Hôpital universitaire Necker-Enfants malades, Paris, France.; General Pediatrics, Infectious Disease and Internal Medicine Department, AP-HP, Hôpital Robert Debré, Reims, France., Koné-Paut I; Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires de l'enfant, Centre Hospitalier Universitaire de Bicêtre, Paris, France., Eulert S; Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany., Kallinich T; Department of Pediatrics, Division of Pneumonology and Immunology with intensive Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany., Berkun Y; Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Mount Scopus, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Uziel Y; Paediatric Rheumatology Unit, Department of Paediatrics, Sackler School of Medicine, Tel-Aviv University, Meir Medical Center, Tel-Aviv, Israel.; Clinical Affairs Committee, Pediatric Rheumatology European Society (PReS), Geneva, Switzerland., Raffeiner B; Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy., Oliveira Ramos F; Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte EPE, Lisboa, Portugal., Clemente D; Paediatric Rheumatology Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain., Dackhammar C; Department of Rheumatology, Sahlgrenska University Hospital, Goteborg, Sweden., Wulffraat NM; Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands.; European Reference Network RITA, Utrecht, Netherlands., Waite H; Atrius Health Inc, Newton, Massachusetts, USA., Strangfeld A; Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany., Mateus EF; Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.; Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), European Alliance of Associations for Rheumatology (EULAR), Kilchberg, Switzerland., Machado PM; Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Natter M; Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA., Hyrich KL; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK kimme.hyrich@manchester.ac.uk.; National Institute of Health Research Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Jazyk:	angličtina
Zdroj:	Annals of the rheumatic diseases [Ann Rheum Dis] 2022 Jul; Vol. 81 (7), pp. 998-1005. Date of Electronic Publication: 2022 Mar 25.
DOI:	10.1136/annrheumdis-2022-222241
Abstrakt:	Objectives: Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19. Methods: Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated. Results: 607 CYP with RMDs <19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12). Conclusions: This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised. Competing Interests: Competing interests: RC reports personal AstraZeneca shares, unrelated to this manuscript. IK-P reports personal fees by Novartis, SOBI, Chugai, Pfizer, AbbVie, BMS, all unrelated to this manuscript. FOR reports consulting/speaker’s fees from Abbvie, Novartis, Pfizer and Sobi, all unrelated to this manuscript. NMW reports personal consultant fees from UCB, BMS, all unrelated to this manuscript. AS reports personal fees from lectures for AbbVie, Celltrion, MSD, Janssen, Lilly, Roche, BMS, and Pfizer, all unrelated to this manuscript. EFM reports personal consultant fees from Boehringer Ingelheim Portugal, Lda, all unrelated to this manuscript. LPCDR received support for specific activities: grants from Abbvie, Novartis, Lilly Portugal, Amgen Biofarmacêutica, Grünenthal S.A., MSD, Medac, A. Menarini Portugal - Farmacêutica, S.A., Pfizer, UCB Pharma, Roche Farmacêutica Química, Lda; and non-financial support from Pfizer, and Grünenthal GmbH, all unrelated to this manuscript.PMM has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre (BRC). MN reports funding from Childhood Arthritis & Rheumatology Research Alliance, Inc (CARRA) to his informatics research and operations group at Boston Children’s Hospital in its capacity as the CARRA Data Warehouse and associated work for CARRA and the CARRA Registry and has sponsored the COVID-19 Global Pediatric Rheumatology Database study, of which he is the Principal Investigator. MN also serves as Director of Informatics for CARRA, for which he receives no direct compensation but do receive research sponsorship for CARRA-related research, development, and operations (see above). He is also a co-investigator of the CARRA Registry and site Principal Investigator at Massachusetts General Hospital. KLH reports non-personal speaker’s fees from Abbvie and grant income from BMS, UCB, and Pfizer, all unrelated to this manuscript, and is supported by the NIHR Manchester Biomedical Research Centre. All other authors report no disclosures. (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu